Meloxicam

Evidence Level: L5

Predicted Indications: 8

Meloxicam

Pharmacist Assessment Report

Meloxicam: From Rheumatoid Arthritis to Acromesomelic Dysplasia, Hunter-Thompson Type

One-Sentence Summary

Meloxicam is a COX-2-preferential NSAID, originally used to treat rheumatoid arthritis, osteoarthritis, juvenile idiopathic arthritis and spondyloarthropathy. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, but no clinical trials and no publications currently support this prediction. It is a TxGNN model (deep learning) prediction only.

Quick Overview

Item	Content
Original Indication	Rheumatoid arthritis (also osteoarthritis, juvenile idiopathic arthritis, spondyloarthropathy)
Predicted New Indication	Acromesomelic dysplasia, Hunter-Thompson type
TxGNN Prediction Score	0.9992
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, meloxicam is an NSAID that inhibits COX-2, and its efficacy in inflammatory joint disease has been established.

The predicted disease is a skeletal dysplasia caused by loss-of-function variants in CDMP1/GDF5. This is a genetic developmental defect, and COX-2 inhibition does not address it. No mechanistic link has been established. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

The same pattern appears in the other top-ranked predictions. Several are rare skeletal or developmental syndromes (brachyolmia, brachyolmia-amelogenesis imperfecta syndrome, pseudoachondroplasia, colobomatous microphthalmia-rhizomelic dysplasia syndrome) or unrelated conditions (WHIM syndrome). Meloxicam might offer symptomatic relief of secondary joint pain in some of them, such as pseudoachondroplasia, but it would not modify the disease. The only prediction with any supporting literature is rheumatoid factor-positive polyarticular juvenile idiopathic arthritis (rank 8, evidence level L4). It is largely an extension of an existing indication, not a novel repurposing.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the top-ranked prediction.

For reference, the only publication in the compiled data relates to the rank 8 prediction (polyarticular JIA):

PMID	Year	Type	Journal	Key Findings
25057265	2014	Safety registry (Phase 4)	Pediatr Rheumatol Online J	Long-term safety and developmental data for celecoxib vs. nonselective NSAIDs in JIA

India Market Information

The 20 valid registrations are all single-ingredient products. The compiled data does not include approved indication text. The main authorizations are:

Authorization Number	Product Name	Dosage Form	Approved Indication
144942	Muvik 15mg Tablet (Lesanto Laboratories)	Strip of 10 tablets	Not available
138452	Movac 15mg Tablet (Alkem Laboratories Ltd)	Strip of 10 tablets	Not available
135516	M-Cam 7.5mg Tablet (Torrent Pharmaceuticals Ltd)	Strip of 10 tablets	Not available
138674	Melotross 5mg Infusion (Kaytross Health Care)	Bottle of 100 ml infusion	Not available
194233	Rafree 7.5mg Tablet (Dr Reddy’s Laboratories Ltd)	Strip of 10 tablets	Not available

Available forms: oral tablets and an intravenous infusion.

Safety Considerations

Contraindications / risk conditions (not label text): hypertension, congestive heart failure, heart disease and cardiovascular disease, myocardial infarction, stroke and cerebrovascular disorders, kidney disease and impaired renal function, active peptic ulcer disease, gastritis, blood coagulation disease, anemia, diabetes mellitus and diabetic ketoacidosis, hyperlipidemia, and substance abuse/dependence.
Drug Interactions: 273 interactions were identified. Those listed are mainly moderate:
- Corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide)
- Acetylsalicylic acid
- Antidiabetic agents (metformin, glimepiride, chlorpropamide)
- Aminosalicylates (mesalazine, balsalazide)
- Aminoglycosides and vancomycin (kanamycin)
- Aprepitant
- Bowel-preparation and potassium products
- Linaclotide (minor)

Please also refer to the package insert for label warnings, which were not available for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by a score from the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence. There are no trials or publications, and no plausible mechanistic link between COX-2 inhibition and a GDF5-related genetic skeletal dysplasia. The cardiovascular, renal and gastrointestinal risk profile of meloxicam also offers no advantage for a non-inflammatory genetic condition.

To proceed, the following is needed:

Package insert warnings and contraindications for the Indian-market products
Detailed mechanism of action data
Preclinical or mechanistic evidence linking COX-2/prostaglandin signalling to GDF5-related skeletal pathology
If a practical direction is wanted, evaluate rank 8 (polyarticular JIA) or symptomatic joint-pain use in pseudoachondroplasia instead, as these are better grounded
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.